亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Asymmetric Synthesis of Norcantharidin Analogues by Alkynylation of Oxabenzonorbornadienes and Their Anticancer Activities

總結: The present invention relates to chemical entities originated from natural sources or obtained from a chemically synthesized compound and further synthesized for therapeutic uses. More particularly, the present invention relates to norcantharidin analogues synthesized by a transition metal-catalyzed alkynylation of oxanorbornadiene derivatives and their antitumor effects.

技術優勢: Reducing the side-effect in the urinary system to some extent and increasing the number of white blood cells with comparable anti-cancer activity

詳細技術說明: The norcantharidin analogues of the present invention are originated from natural sources and further synthesized into at least three different compounds. using an Ir catalyst to carry out transition metal-catalyzed alkynylation of oxanorbornadiene derivatives.

附加資料: Inventor: Chan, Albert Sun-Chi | Fan, Baomin | Wang, Jun | Lin, Chengyuan | Huang, Chao | Yang, Qingjing | Xu, Jianbin | Bian, Zhaoxiang | Lu, Aiping | Hu, Jun
Priority Number: US8835658B2
IPC Current: C07D030700 | C07D049308
US Class: 549459
Assignee Applicant: Hong Kong Baptist University
Title: Asymmetric synthesis of norcantharidin analougus by alkynylation of oxabenzonorbornadienes and their anticancer activities
Usefulness: Asymmetric synthesis of norcantharidin analougus by alkynylation of oxabenzonorbornadienes and their anticancer activities
Summary: (I) is useful for treating cancer tumors including colorectal carcinoma and breast adenocarcinoma (all claimed). Test details are described but no results given.
Novelty: Synthesizing norcantharidin compounds, useful for treating cancer tumors e.g. colorectal carcinoma, comprises alkynylation of oxabenzonorbornadienes in presence of catalyst including transition metal compound and biaryl diphosphine ligand

欲了解更多信息，請點擊這裡